![Patricia Allen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patricia Allen
Director/Board Member at
Inversago Pharma, Inc.
Net worth: 504 047 $ as of 2026-06-29
Profile
Patricia L.
Allen is currently Director at Anokion SA since 2020, Director at Kanyos Bio, Inc., Independent Director at Inversago Pharma, Inc., Non-Executive Director at SwanBio Therapeutics, Inc. since 2020, and Independent Director at Zenas BioPharma, Inc. since 2024.
Former roles include Finance Director at Alkermes, Inc. from 1992 to 2004, Director at Yumanity, Inc. from 2019 to 2020, Independent Director at Deciphera Pharmaceuticals, Inc. from 2016 to 2024, Independent Director at Yumanity Therapeutics, Inc. from 2020 to 2022, CFO, Treasurer & Principal Accounting Officer at Zafgen, Inc. from 2013 to 2020, Auditor at Deloitte & Touche LLP, Chief Financial Officer, Treasurer & VP at Alnylam Pharmaceuticals, Inc. in 2010, and Chief Financial Officer at Vividion Therapeutics, Inc. from 2021 to 2024.
Education includes undergraduate studies at Bryant University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
0.03% | 2026-06-14 | 19,860 ( 0.03% ) | 504 047 $ | 2026-06-29 |
Patricia Allen active positions
| Companies | Position | Start |
|---|---|---|
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops CB1 receptor based therapies for obesity, diabetes and complication treatment | Director/Board Member | - |
Anokion SA
 Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance | Director/Board Member | 2020-09-28 |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage gene therapy company that develops therapeutics for neurological disorders | Director/Board Member | 2020-11-19 |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Director/Board Member | - |
Former positions of Patricia Allen
| Companies | Position | End |
|---|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Director/Board Member | 2024-06-10 |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Director of Finance/CFO | 2023-12-31 |
| YUMANITY THERAPEUTICS | Director/Board Member | 2022-11-30 |
Yumanity, Inc.
 Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Provides transforming drug discovery for neurodegenerative diseases services | Director/Board Member | 2020-12-21 |
| LARIMAR THERAPEUTICS, INC. | Director of Finance/CFO | 2020-04-30 |
Training of Patricia Allen
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
66
1st degree connections
13
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 13 |
|---|---|
Alkermes, Inc.
 Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical products | Health Technology |
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, financial advisory and tax consulting services | Commercial Services |
Alnylam Pharmaceuticals, Inc.
 Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Bryant University
 Bryant University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anokion SA
Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance | Health Technology |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Health Technology |
Yumanity, Inc.
Yumanity, Inc. Pharmaceuticals: MajorHealth Technology Provides transforming drug discovery for neurodegenerative diseases services | Health Technology |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Health Technology |
Deciphera Pharmaceuticals, Inc.
 Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drug candidates to improve the lives of cancer patients | Health Technology |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops CB1 receptor based therapies for obesity, diabetes and complication treatment | Health Technology |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage gene therapy company that develops therapeutics for neurological disorders | Health Technology |
Yumanity Therapeutics, Inc.
 Yumanity Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
- Stock Market
- Insiders
- Patricia Allen
